Ketamine and Its Effect on Alzheimer's Disease by Quieting the DMN

There is some evidence to suggest that ketamine, a dissociative anesthetic and rapid-acting antidepressant, may have the potential to prevent or delay the onset of Alzheimer's disease by quieting the Default Mode Network (DMN).

Studies have shown that ketamine can decrease the activity of the DMN, which may help reduce the accumulation of beta-amyloid plaques, a hallmark feature of Alzheimer's disease. In addition, ketamine has been shown to stimulate the growth of new neural connections, which could potentially help offset the neurodegenerative effects of Alzheimer's disease.

However, it's important to note that the use of ketamine for preventing or treating Alzheimer's disease is still in the early stages of research, and more studies are needed to fully understand its potential benefits and risks. Moreover, the long-term effects of ketamine use are not yet fully understood, and it is not currently approved by the FDA for the treatment of Alzheimer's disease.

Overall, while ketamine may have some potential as a preventative measure for Alzheimer's disease, it is not yet a proven or widely accepted treatment option for this condition. As with any medical treatment, individuals should consult with their healthcare provider to determine the best course of action for their individual needs and medical history.